Key result
Review summarizes clinical trials, guidelines, and pharmacology for anticoagulation in the cardiac cath lab.
Why the study?
The correct choice of anticoagulation during percutaneous coronary interventions can maximize patient outcomes and ensure a safe procedure, though in specific situations anticoagulation may not be required.
This review summarizes the clinical data, guidelines, and pharmacological aspects of anticoagulation use during percutaneous coronary interventions.
Synthesizes anticoagulation evidence for PCI; leaves open optimal regimens amid evolving therapies and patient subsets.
Anticoagulation during percutaneous coronary interventions has a rich history that has been shaped by several key clinical trials. The correct choice of anticoagulation during interventions can maximize patient outcomes and ensure a safe procedure. However, in some specific situations, anticoagulation may not be required at all. In this review article, we review the significant clinical trials and current guidelines regarding the use of anticoagulation in the catheterization laboratory and discuss the unique pharmacological aspects of the most commonly used agents, with an emphasis on the specific pharmacokinetic parameters that dictate how these agents are used and monitored. Finally, we discussed the future directions in anticoagulation therapy in coronary artery disease. This review serves as a robust synopsis of the clinical data for practicing clinicians and fellows in training.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a review in Coronary artery disease requiring percutaneous coronary interventions. Anticoagulation was evaluated. This review summarizes significant clinical trials, current guidelines, and pharmacological aspects regarding the use of anticoagulation in the cardiac catheterization laboratory.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: